Eukaryotic expression and bioactivity determination of the fusion protein sTNFRII-gAD consisting of soluble tumor necrosis factor receptor II and globular domain of adiponectin

Shengwu Gongcheng Xuebao/Chinese Journal of Biotechnology

Volumn 26, Issue 2, 2010, Pages 207-215

  Chen, Suyun ^a,b   He, Qiushan ^c   Dong, Xiaoyan ^b,d   Wu, Xiaobing ^b   Gao, Jimin ^a,c  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

^d Beijing Fiveplus Molecular Medicine Institute   (China)

Author keywords

Adiponectin; Eukaryotic expression; Fusion protein; Soluble TNF receptor II; TNF antagonist

Indexed keywords

ADIPONECTIN; HYBRID PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 2;

ANIMAL; ARTICLE; BIOSYNTHESIS; CELL CULTURE; DRUG ANTAGONISM; GENETICS; HAMSTER; HUMAN; PROTEIN TERTIARY STRUCTURE; SOLUBILITY;

ADIPONECTIN; ANIMALS; CELLS, CULTURED; CRICETINAE; HUMANS; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; RECOMBINANT FUSION PROTEINS; SOLUBILITY; TUMOR NECROSIS FACTOR-ALPHA;

EUKARYOTA; MAMMALIA;

EID: 77954774212     PISSN: 10003061     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Taylor PC, Williams RO, Feldmann M. Tumour necrosis factor alpha as a therapeutic target for immune-mediated inflammatory diseases. Curr Opin Biotechnol, 2004, 15(6): 557-563.
2. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther, 2008, 117(2): 244-279.
3. Mohler KM, Torrance DS, Smith CA, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol, 1993, 151(3): 1548-1561.
4. Smith RA, Baglioni C. The active form of tumor necrosis factor is a trimer. J Biol Chem, 1987, 562(15): 6951-6954.
5. Jones EY, Stuart DI, Walker NP. Structure of tumour necrosis factor. Nature, 1989, 338(6212): 225-228.
6. Shapiro L, Scherer PE. The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor. Curr Biol, 1998, 8(6): 335-338.
7. Zhang Y, Gao K, Han CM, et al. Study on methods and requirements for quality control of recombinant human tumor necrosis factor receptor Fc fusion protein. Acta Pharm Sin, 2003, 38(3): 165-168.
8. Keffer J, Probert L, Cazlaris H, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J, 1991, 10(13): 4025-4031.
9. Fernandez-Botran R. Soluble cytokine receptors: novel immunotherapeutic agents. Expert Opin Investig Drugs, 2000, 9(3): 497-514.
10. Scherer PE, Williams S, Fogliano M, et al. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem, 1995, 270(45): 26746-26749.
11. Nakano Y, Tobe T, Choi-Miura NH, et al. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem, 1996, 120(4): 803-812.
12. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem, 1996, 271(18): 10697-10703.
13. Maeda K, Okubo K, Shimomura J, et al. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun, 1996, 221(2): 286-289.
14. Fruebis J, Tsao TS, Javorschi S, et al. Proteolytic cleavage product of 30 kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA, 2001, 98(4): 2005-2010.
15. Tannous BA, Kim DE, Fernandez JL, et al. Codonoptimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo. Mol Ther, 2005, 11(3): 435-443.